Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advan
Safety profile to date with continuous daily dosing supports continued dose optimization and clinica
Safety profile to date with continuous daily dosing supports continued dose optimization and clinica